Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
Interleukin-2 (IL-2) is a T-cell proliferating factor used for cancer immunotherapy. Here, the authors develop a long-lived variant of IL-2 that, mutated in its binding domain, drives a much more potent tumour regression by depleting CD25+ CD4+regulatory T-cells via targeting them for phagocytosis.
Main Authors: | Rodrigo Vazquez-Lombardi, Claudia Loetsch, Daniela Zinkl, Jennifer Jackson, Peter Schofield, Elissa K. Deenick, Cecile King, Tri Giang Phan, Kylie E. Webster, Jonathan Sprent, Daniel Christ |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2017-05-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/ncomms15373 |
Similar Items
-
Antitumour Activity of a Hinge- and Fc-engineered Chimeric Heavy-chain Antibody
by: D'Eall, Calvin
Published: (2015) -
The neonatal Fc receptor in cancer FcRn in cancer
by: Diana Cadena Castaneda, et al.
Published: (2020-07-01) -
The Neonatal Fc Receptor (FcRn): A Misnomer?
by: Michal Pyzik, et al.
Published: (2019-07-01) -
An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIaV158 Reveals That Ligation of FcγRIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis With GM-CSF-Differentiated Macrophages
by: Tae Hyun Kang, et al.
Published: (2019-03-01) -
Characterization of the rabbit neonatal Fc receptor (FcRn) and analyzing the immunophenotype of the transgenic rabbits that overexpresses FcRn.
by: Ana Paula Catunda Lemos, et al.
Published: (2012-01-01)